SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
CTIC Analysis & Videos »
CTIC: Bull or Bear?
FDA Extreme Trades: 16 Stocks Under $5
CTIC
|
|
|
-28.65%
in
13 days
<> Below are FDA extreme trades among 16 companies with stock prices under $5 from the <font> BioMedReports.com FDA Calendar </font> (database includes 225 entries as of 6/27/09) which have pending FDA decisions for either new drug products, biological agents, medical devices, or diagnostic tests that may have a major impact on each of the underlying stock prices. A high risk/reward trading approach to consider for speculative traders is investing a small amount of money that you can afford to lose in a basket of stocks included in <> <font> Extreme FDA and Clinical Trial Calendar Trade...
|
Lixte Biotech (OTC:LIXT): Key 2H09 Catalysts Await
CTIC
|
|
|
+31.21%
in
4 days
(closed on 06/27/09)
<> Since I first wrote about Lixte Biotech (OTC:LIXT) at <font> BioMedReports.com in early April </font> , the Company has provided an update on its development-stage cancer drug discovery operations as part of a SEC 10Q filing in mid-May for 1Q09. LIXT.OB was originally founded as a diagnostics company in 2005 evaluating biomarkers (indicators of disease at the molecular level), but has shifted its focus to cancer drug discovery research that is primarily focused on the development of compounds for malignancies with few effective treatment options – such as certain types of brain cancer<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>...
|
Access Pharma: A Cancer Biotech Call Option Trade
CTIC
|
|
|
+13.72%
in
27 days
(closed on 06/23/09)
<> The cancer biotech space has attracted the interest of investors, traders, and diversified healthcare giants this year with Johnson & Johnson (NYSE: JNJ) announcing a $1B cash tender offer for Cougar Biotech (NASDAQ: CGRB) last week and Roche's (VTX: ROG) (OTC: RHHBY) mega-deal to acquire full control of Genentech earlier this year. In addition, positive clinical trial results for Dendreon's (NASDAQ: DNDN) Provenge and stock price turnarounds from the brink of zero at Cell Therapeutics (NASDAQ: CTIC) have fueled interest in the small and micro-cap cancer bio-pharma space among investors an...
|
Clinical Trial Updates: Cancer Drugs in Focus as ASCO Approaches
CTIC
|
|
|
+4.19%
in
10 days
(closed on 05/27/09)
<> Below is a summary of updates to the <font> BioMedReports.com </font> database of over 200 entries included in the <font> FDA and Clinical Trial Calendars </font> . The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA fo...
|
Cell Therapeutics Sells $20M in Stock, Warrants
CTIC
|
|
|
-26.54%
in
6 days
(closed on 05/17/09)
After the market close, Cell Therapeutics (NASDAQ:CTIC) announced the sale of $20M of its common stock at $1.25 per share along with warrant coverage to a single institutional investor. CTIC plans to use $17.8M in cash on hand and/or raised through this sale to pay for its anticipated 'Modified Dutch Auction' tender offer to retire between $83.2-89.2 million of convertible debt within an expected range of $250-300 per $1,000 par value of the bonds. <> The sale announced today includes 30% warrant coverage on the $20M offering price with an exercise price of $1.40 pe...
|
Cell Therapeutics: Turnaround Remains On Track
CTIC
|
|
|
+51.40%
in
4 days
(closed on 05/11/09)
The dramatic turnaround from lows of a nickel per share ealier this year at cancer biotech Cell Therapeutics (NASDAQ:CTIC) remains on track as the Company announced its 1Q09 results today, which included a 76% reduction of net loss and expected completion of the pixantrone NDA filing this June. Earlier this week, CTIC announced that pixantrone was made available through a compassionate use program in Europe on a named-patient basis for use in the treatment of aggressive non-Hodgkin's lymphoma (NHL) that has either relapsed or is refractory to standard treatment options. <> CTIC a...
|
Cell Therapeutics Inc rebounds after offer rejection
CTIC
|
|
|
-1.94%
in
6 days
(closed on 04/19/07)
Background: Cell Therapeutics, Inc. engages in the development, acquisition, and commercialization of treatments for cancer. The company offers XYOTAX, a Phase III clinical trial chemotherapeutic agent, which links anti cancer agent called paclitaxel to a polyglutamate polymer for the treatment of non-small cell lung cancer and ovarian cancers in females. finance.yahoo.com/q/pr
Recent News:
DOR rejects buyout offer
April 12, 2007: DOR BioPharma said its board has rejected a buyout offer from Cell Therapeutics as being "inadequate for shareholders." <>biz.yahoo.com/bizj/...
|
People Bullish on CTIC
People Bearish on CTIC
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on CTIC |
Chart Alerts for April 14
- Here is a link to some chart alerts for April 14th
http://www.stockhideout.com/sas-nightly-chart-scans/2809-chart-alerts-april-14-a.html
|
More Resources
|
About Cell Therapeutics Inc
- Answers.com
